drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00688 | DB06372 | 955 | 259 | [
"DDInter1251",
"DDInter1594"
] | Mycophenolate mofetil | Rilonacept | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
955,
24,
259
]
],
[
[
955,
23,
1114
],
[
1114,
62,
259
]
],
[
[
955,
24,
270
],
[
270,
63,
259
]
],
[
[
955,
24,
4
],
[
4,
24,
... | [
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Mycophenolate mofetil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc su... | Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with... |
DB01001 | DB01244 | 688 | 762 | [
"DDInter1632",
"DDInter192"
] | Salbutamol | Bepridil | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Moderate | 1 | [
[
[
688,
24,
762
]
],
[
[
688,
63,
939
],
[
939,
40,
762
]
],
[
[
688,
21,
28698
],
[
28698,
60,
762
]
],
[
[
688,
62,
112
],
[
112,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bepridil"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
],
[
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Bepridil (Compound)
Salbutamol (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Bepridil (Compound)
Salbutamol may cause a minor interaction tha... |
DB00557 | DB01268 | 252 | 1,151 | [
"DDInter895",
"DDInter1731"
] | Hydroxyzine | Sunitinib | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
252,
24,
1151
]
],
[
[
252,
24,
1311
],
[
1311,
1,
1151
]
],
[
[
252,
21,
28680
],
[
28680,
60,
1151
]
],
[
[
252,
23,
112
],
[
112,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
... | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Hydroxyzine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Sunitinib (Compound)
Hydroxyzine may cause a minor interaction that... |
DB00046 | DB13928 | 1,179 | 1,385 | [
"DDInter940",
"DDInter1660"
] | Insulin lispro | Semaglutide | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1179,
24,
1385
]
],
[
[
1179,
23,
1103
],
[
1103,
23,
1385
]
],
[
[
1179,
24,
1154
],
[
1154,
24,
1385
]
],
[
[
1179,
24,
1399
],
[
13... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
... | Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and ... |
DB00834 | DB12130 | 932 | 1,017 | [
"DDInter1215",
"DDInter1094"
] | Mifepristone | Lorlatinib | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
932,
24,
1017
]
],
[
[
932,
63,
608
],
[
608,
23,
1017
]
],
[
[
932,
62,
1101
],
[
1101,
23,
1017
]
],
[
[
932,
63,
590
],
[
590,
... | [
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[... | Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarote... |
DB01018 | DB01069 | 1,364 | 401 | [
"DDInter847",
"DDInter1533"
] | Guanfacine | Promethazine | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1364,
24,
401
]
],
[
[
1364,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1364,
63,
104
],
[
104,
24,
401
]
],
[
[
1364,
6,
6017
],
[
6017,
... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdila... |
DB01619 | DB08883 | 830 | 1,597 | [
"DDInter1441",
"DDInter1428"
] | Phenindamine | Perampanel | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning ... | Moderate | 1 | [
[
[
830,
24,
1597
]
],
[
[
830,
63,
100
],
[
100,
24,
1597
]
],
[
[
830,
40,
104
],
[
104,
24,
1597
]
],
[
[
830,
1,
537
],
[
537,
2... | [
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],... | Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Phenindamine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate inte... |
DB12001 | DB12095 | 564 | 179 | [
"DDInter7",
"DDInter1760"
] | Abemaciclib | Telotristat ethyl | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
564,
24,
179
]
],
[
[
564,
63,
1213
],
[
1213,
24,
179
]
],
[
[
564,
24,
283
],
[
283,
63,
179
]
],
[
[
564,
25,
676
],
[
676,
6... | [
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
... | Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and... |
DB00518 | DB04865 | 510 | 4 | [
"DDInter35",
"DDInter1335"
] | Albendazole | Omacetaxine mepesuccinate | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
510,
24,
4
]
],
[
[
510,
18,
10351
],
[
10351,
46,
4
]
],
[
[
510,
7,
6461
],
[
6461,
46,
4
]
],
[
[
510,
6,
9842
],
[
9842,
46,... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Albendazole",
"{u} (Compound) downregulates {v} (Gene)",
"ATF6"
],
[
"ATF6",
"{u} (Gene) is upre... | Albendazole (Compound) downregulates ATF6 (Gene) and ATF6 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Albendazole (Compound) upregulates DDX10 (Gene) and DDX10 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Albendazole (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregulated by O... |
DB00341 | DB01148 | 1,242 | 1,128 | [
"DDInter343",
"DDInter738"
] | Cetirizine | Flavoxate | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
1242,
24,
1128
]
],
[
[
1242,
40,
11268
],
[
11268,
40,
1128
]
],
[
[
1242,
21,
28748
],
[
28748,
60,
1128
]
],
[
[
1242,
24,
537
],
[
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound)",
"Cloperastine"
],
[
"Cloperastine",
"{u} (Compound) resem... | Cetirizine (Compound) resembles Cloperastine (Compound) and Cloperastine (Compound) resembles Flavoxate (Compound)
Cetirizine (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Flavoxate (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyc... |
DB00067 | DB01611 | 317 | 1,487 | [
"DDInter1921",
"DDInter893"
] | Vasopressin | Hydroxychloroquine | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
317,
25,
1487
]
],
[
[
317,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
317,
63,
521
],
[
521,
24,
1487
]
],
[
[
317,
24,
147
],
[
147,
... | [
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"... | Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin ma... |
DB01168 | DB01612 | 1,053 | 1,637 | [
"DDInter1526",
"DDInter92"
] | Procarbazine | Amyl Nitrite | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
1053,
24,
1637
]
],
[
[
1053,
64,
946
],
[
946,
24,
1637
]
],
[
[
1053,
25,
180
],
[
180,
63,
1637
]
],
[
[
1053,
25,
993
],
[
993,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Buspirone"
],
[
"Buspi... | Procarbazine may lead to a major life threatening interaction when taken with Buspirone and Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Procarbazine may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderat... |
DB00668 | DB09045 | 874 | 52 | [
"DDInter652",
"DDInter607"
] | Epinephrine | Dulaglutide | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
874,
24,
52
]
],
[
[
874,
24,
170
],
[
170,
23,
52
]
],
[
[
874,
63,
73
],
[
73,
24,
52
]
],
[
[
874,
24,
879
],
[
879,
24,
... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Ph... |
DB00983 | DB09045 | 480 | 52 | [
"DDInter776",
"DDInter607"
] | Formoterol | Dulaglutide | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
480,
24,
52
]
],
[
[
480,
24,
170
],
[
170,
23,
52
]
],
[
[
480,
24,
280
],
[
280,
24,
52
]
],
[
[
480,
63,
73
],
[
73,
24,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Me... |
DB01377 | DB11613 | 1,283 | 1,519 | [
"DDInter1119",
"DDInter1924"
] | Magnesium oxide | Velpatasvir | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Moderate | 1 | [
[
[
1283,
24,
1519
]
],
[
[
1283,
24,
594
],
[
594,
24,
1519
]
],
[
[
1283,
62,
1559
],
[
1559,
24,
1519
]
],
[
[
1283,
24,
1040
],
[
1040... | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]... | Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Famotidine and... |
DB00341 | DB01178 | 1,242 | 369 | [
"DDInter343",
"DDInter357"
] | Cetirizine | Chlormezanone | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. | Moderate | 1 | [
[
[
1242,
24,
369
]
],
[
[
1242,
24,
1532
],
[
1532,
63,
369
]
],
[
[
1242,
24,
272
],
[
272,
24,
369
]
],
[
[
1242,
74,
701
],
[
701,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine a... |
DB01377 | DB14006 | 1,283 | 972 | [
"DDInter1119",
"DDInter370"
] | Magnesium oxide | Choline salicylate | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Moderate | 1 | [
[
[
1283,
24,
972
]
],
[
[
1283,
62,
1573
],
[
1573,
24,
972
]
],
[
[
1283,
24,
286
],
[
286,
24,
972
]
],
[
[
1283,
63,
1411
],
[
1411,
... | [
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisone"... | Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magne... |
DB00575 | DB09564 | 1,020 | 1,296 | [
"DDInter412",
"DDInter930"
] | Clonidine | Insulin degludec | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1020,
24,
1296
]
],
[
[
1020,
24,
274
],
[
274,
23,
1296
]
],
[
[
1020,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1020,
63,
999
],
[
999,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
],
... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and... |
DB11760 | DB11915 | 119 | 1,293 | [
"DDInter1742",
"DDInter1909"
] | Talazoparib | Valbenazine | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
119,
24,
1293
]
],
[
[
119,
63,
392
],
[
392,
24,
1293
]
],
[
[
119,
24,
1619
],
[
1619,
63,
1293
]
],
[
[
119,
63,
384
],
[
384,
... | [
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
... | Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapa... |
DB00374 | DB00883 | 1,061 | 426 | [
"DDInter1852",
"DDInter989"
] | Treprostinil | Isosorbide dinitrate | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | A vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action. | Moderate | 1 | [
[
[
1061,
24,
426
]
],
[
[
1061,
24,
1107
],
[
1107,
1,
426
]
],
[
[
1061,
54,
19134
],
[
19134,
15,
426
]
],
[
[
1061,
21,
29118
],
[
291... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isosorbide dinitrate"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isosorbide mo... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Isosorbide mononitrate and Isosorbide mononitrate (Compound) resembles Isosorbide dinitrate (Compound)
Treprostinil (Compound) is included by Vasodilation (Pharmacologic Class) and Vasodilation (Pharmacologic Class) includes Is... |
DB01097 | DB14762 | 1,377 | 994 | [
"DDInter1033",
"DDInter1602"
] | Leflunomide | Risankizumab | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Major | 2 | [
[
[
1377,
25,
994
]
],
[
[
1377,
23,
1114
],
[
1114,
23,
994
]
],
[
[
1377,
62,
1461
],
[
1461,
23,
994
]
],
[
[
1377,
25,
4
],
[
4,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risankizumab"
]
],
[
[
"Leflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc s... | Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitam... |
DB00761 | DB00831 | 1,621 | 1,178 | [
"DDInter1497",
"DDInter1866"
] | Potassium chloride | Trifluoperazine | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Major | 2 | [
[
[
1621,
25,
1178
]
],
[
[
1621,
64,
695
],
[
695,
40,
1178
]
],
[
[
1621,
25,
146
],
[
146,
40,
1178
]
],
[
[
1621,
25,
9
],
[
9,
... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Cloza... | Potassium chloride may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Potassium chloride may lead to a major life threatening interaction when taken with Propiomazine and Propiomazine (Compound) resembles Trifluoperazine (Compound)
Po... |
DB00254 | DB01253 | 964 | 628 | [
"DDInter598",
"DDInter664"
] | Doxycycline | Ergometrine | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Moderate | 1 | [
[
[
964,
24,
628
]
],
[
[
964,
63,
1131
],
[
1131,
40,
628
]
],
[
[
964,
24,
588
],
[
588,
40,
628
]
],
[
[
964,
6,
8374
],
[
8374,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ergometrine"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methysergide"
],
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Methysergide and Methysergide (Compound) resembles Ergometrine (Compound)
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Methylergometrine and Methylergometrine (Compound) resembles E... |
DB00041 | DB01222 | 1,648 | 617 | [
"DDInter38",
"DDInter246"
] | Aldesleukin | Budesonide | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1648,
24,
617
]
],
[
[
1648,
24,
251
],
[
251,
1,
617
]
],
[
[
1648,
24,
1560
],
[
1560,
24,
617
]
],
[
[
1648,
24,
1531
],
[
1531,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interactio... |
DB00884 | DB00994 | 1,008 | 361 | [
"DDInter1604",
"DDInter1277"
] | Risedronic acid | Neomycin | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Moderate | 1 | [
[
[
1008,
24,
361
]
],
[
[
1008,
21,
28722
],
[
28722,
60,
361
]
],
[
[
1008,
63,
1132
],
[
1132,
24,
361
]
],
[
[
1008,
40,
1485
],
[
148... | [
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
]
],
[
[
"Risedronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is ca... | Risedronic acid (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Neomycin (Compound)
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Neomy... |
DB12015 | DB14840 | 1,033 | 861 | [
"DDInter53",
"DDInter1601"
] | Alpelisib | Ripretinib | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolis... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
1033,
24,
861
]
],
[
[
1033,
63,
351
],
[
351,
24,
861
]
],
[
[
1033,
24,
1017
],
[
1017,
24,
861
]
],
[
[
1033,
63,
384
],
[
384,
... | [
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatin... |
DB00938 | DB01234 | 455 | 1,220 | [
"DDInter1635",
"DDInter513"
] | Salmeterol | Dexamethasone | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Minor | 0 | [
[
[
455,
23,
1220
]
],
[
[
455,
62,
870
],
[
870,
1,
1220
]
],
[
[
455,
62,
175
],
[
175,
40,
1220
]
],
[
[
455,
23,
617
],
[
617,
4... | [
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
],
... | Salmeterol may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamet... |
DB00222 | DB01037 | 245 | 1,161 | [
"DDInter825",
"DDInter1653"
] | Glimepiride | Selegiline | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Moderate | 1 | [
[
[
245,
24,
1161
]
],
[
[
245,
24,
551
],
[
551,
1,
1161
]
],
[
[
245,
24,
280
],
[
280,
40,
1161
]
],
[
[
245,
6,
6017
],
[
6017,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Selegiline (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Mephentermine and Mephentermine (Compound) resembles Selegiline (Co... |
DB00476 | DB00712 | 109 | 1,274 | [
"DDInter608",
"DDInter763"
] | Duloxetine | Flurbiprofen | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
109,
24,
1274
]
],
[
[
109,
21,
28769
],
[
28769,
60,
1274
]
],
[
[
109,
23,
1127
],
[
1127,
23,
1274
]
],
[
[
109,
23,
1559
],
[
1559... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Duloxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side... | Duloxetine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofen (Compound)
Duloxetine may cause a minor interaction that can limit clinical effects when taken with Nizatidine and Nizatidine may cause a minor interaction that can limit clinical effects when taken ... |
DB00307 | DB00425 | 1,101 | 558 | [
"DDInter202",
"DDInter1970"
] | Bexarotene | Zolpidem | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Moderate | 1 | [
[
[
1101,
24,
558
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
558
]
],
[
[
1101,
21,
29351
],
[
29351,
60,
558
]
],
[
[
1101,
24,
868
],
[
868,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zolpidem (Compound)
Bexarotene (Compound) causes Phosphatase alkaline increased (Side Effect) and Phosphatase alkaline increased (Side Effect) is caused by Zolpidem (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseas... |
DB00744 | DB08912 | 1,288 | 1,040 | [
"DDInter1962",
"DDInter462"
] | Zileuton | Dabrafenib | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1288,
24,
1040
]
],
[
[
1288,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
1288,
21,
29220
],
[
29220,
60,
1040
]
],
[
[
1288,
24,
478
],
[
47... | [
[
[
"Zileuton",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Zileuton",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Zileuton (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Zileuton (Compound) causes Abdominal pain upper (Side Effect) and Abdominal pain upper (Side Effect) is caused by Dabrafenib (Compound)
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Nil... |
DB00262 | DB01165 | 552 | 1,539 | [
"DDInter302",
"DDInter1325"
] | Carmustine | Ofloxacin | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Minor | 0 | [
[
[
552,
23,
1539
]
],
[
[
552,
23,
1467
],
[
1467,
1,
1539
]
],
[
[
552,
62,
1176
],
[
1176,
1,
1539
]
],
[
[
552,
23,
945
],
[
945,
... | [
[
[
"Carmustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Carmustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"En... | Carmustine may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Carmustine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Carmus... |
DB00099 | DB01005 | 440 | 995 | [
"DDInter735",
"DDInter894"
] | Filgrastim | Hydroxyurea | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Moderate | 1 | [
[
[
440,
24,
995
]
],
[
[
440,
24,
1238
],
[
1238,
24,
995
]
],
[
[
440,
24,
869
],
[
869,
63,
995
]
],
[
[
440,
63,
1648
],
[
1648,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topo... |
DB08899 | DB14840 | 129 | 861 | [
"DDInter649",
"DDInter1601"
] | Enzalutamide | Ripretinib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Major | 2 | [
[
[
129,
25,
861
]
],
[
[
129,
25,
351
],
[
351,
24,
861
]
],
[
[
129,
63,
353
],
[
353,
24,
861
]
],
[
[
129,
40,
918
],
[
918,
24,... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ripretinib"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{... | Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin ma... |
DB01115 | DB01166 | 336 | 477 | [
"DDInter1291",
"DDInter379"
] | Nifedipine | Cilostazol | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
336,
24,
477
]
],
[
[
336,
6,
8374
],
[
8374,
45,
477
]
],
[
[
336,
7,
4450
],
[
4450,
46,
477
]
],
[
[
336,
10,
11573
],
[
11573,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Nifedipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Nifedipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Nifedipine (Compound) upregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Cilostazol (Compound)
Nifedipine (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) is palliated by Cilostazol... |
DB00377 | DB06788 | 1,494 | 1,616 | [
"DDInter1382",
"DDInter864"
] | Palonosetron | Histrelin | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1494,
24,
1616
]
],
[
[
1494,
23,
112
],
[
112,
23,
1616
]
],
[
[
1494,
24,
1664
],
[
1664,
24,
1616
]
],
[
[
1494,
64,
1251
],
[
1251... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and ... |
DB00637 | DB09082 | 1,557 | 659 | [
"DDInter128",
"DDInter1934"
] | Astemizole | Vilanterol | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1557,
24,
659
]
],
[
[
1557,
63,
1570
],
[
1570,
24,
659
]
],
[
[
1557,
24,
927
],
[
927,
63,
659
]
],
[
[
1557,
25,
1069
],
[
1069,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and E... |
DB00108 | DB09570 | 1,066 | 1,480 | [
"DDInter1268",
"DDInter1002"
] | Natalizumab | Ixazomib | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Major | 2 | [
[
[
1066,
25,
1480
]
],
[
[
1066,
24,
987
],
[
987,
63,
1480
]
],
[
[
1066,
64,
268
],
[
268,
24,
1480
]
],
[
[
1066,
25,
453
],
[
453,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live an... | Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Natalizumab may lead to a major life th... |
DB09263 | DB13749 | 1,436 | 1,473 | [
"DDInter1399",
"DDInter1116"
] | Patiromer | Magnesium gluconate | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts and is used as a mineral supplement. Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an... | Moderate | 1 | [
[
[
1436,
24,
1473
]
],
[
[
1436,
63,
544
],
[
544,
24,
1473
]
],
[
[
1436,
24,
853
],
[
853,
24,
1473
]
],
[
[
1436,
63,
544
],
[
544,
... | [
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
]
],
[
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
... | Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Patiromer may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00072 | DB00363 | 550 | 695 | [
"DDInter1846",
"DDInter419"
] | Trastuzumab | Clozapine | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Major | 2 | [
[
[
550,
25,
695
]
],
[
[
550,
24,
126
],
[
126,
63,
695
]
],
[
[
550,
24,
738
],
[
738,
64,
695
]
],
[
[
550,
25,
51
],
[
51,
64,
... | [
[
[
"Trastuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Clozapine
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib ... |
DB00574 | DB00758 | 121 | 1,347 | [
"DDInter717",
"DDInter413"
] | Fenfluramine | Clopidogrel | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
121,
24,
1347
]
],
[
[
121,
63,
1018
],
[
1018,
25,
1347
]
],
[
[
121,
24,
1411
],
[
1411,
62,
1347
]
],
[
[
121,
63,
245
],
[
245,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide m... |
DB00254 | DB09268 | 964 | 1,662 | [
"DDInter598",
"DDInter1464"
] | Doxycycline | Picosulfuric acid | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
964,
24,
1662
]
],
[
[
964,
24,
1482
],
[
1482,
23,
1662
]
],
[
[
964,
23,
997
],
[
997,
24,
1662
]
],
[
[
964,
24,
319
],
[
319,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Doxycycline may cause a minor interaction that can limit clinical effects when taken with Methazolamide and ... |
DB00619 | DB14444 | 1,419 | 151 | [
"DDInter909",
"DDInter924"
] | Imatinib | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
1419,
24,
151
]
],
[
[
1419,
63,
66
],
[
66,
24,
151
]
],
[
[
1419,
24,
1619
],
[
1619,
24,
151
]
],
[
[
1419,
35,
1468
],
[
1468,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exace... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Imatinib may cause a moderate interacti... |
DB01159 | DB09078 | 419 | 1,228 | [
"DDInter854",
"DDInter1036"
] | Halothane | Lenvatinib | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
419,
24,
1228
]
],
[
[
419,
62,
112
],
[
112,
23,
1228
]
],
[
[
419,
24,
609
],
[
609,
24,
1228
]
],
[
[
419,
63,
1264
],
[
1264,
... | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Halothane",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Halothane may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Cl... |
DB04844 | DB09080 | 843 | 144 | [
"DDInter1778",
"DDInter1331"
] | Tetrabenazine | Olodaterol | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
843,
24,
144
]
],
[
[
843,
25,
1011
],
[
1011,
24,
144
]
],
[
[
843,
64,
11
],
[
11,
24,
144
]
],
[
[
843,
63,
543
],
[
543,
24,... | [
[
[
"Tetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fing... | Tetrabenazine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Tetrabenazine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderat... |
DB01110 | DB01125 | 86 | 279 | [
"DDInter1209",
"DDInter98"
] | Miconazole | Anisindione | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Major | 2 | [
[
[
86,
25,
279
]
],
[
[
86,
63,
467
],
[
467,
23,
279
]
],
[
[
86,
63,
1195
],
[
1195,
24,
279
]
],
[
[
86,
62,
222
],
[
222,
24,
... | [
[
[
"Miconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvasta... | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Anisindione
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erloti... |
DB00041 | DB01610 | 1,648 | 248 | [
"DDInter38",
"DDInter1912"
] | Aldesleukin | Valganciclovir | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
1648,
24,
248
]
],
[
[
1648,
24,
563
],
[
563,
1,
248
]
],
[
[
1648,
24,
1238
],
[
1238,
24,
248
]
],
[
[
1648,
25,
507
],
[
507,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may cause a moderate interaction ... |
DB05273 | DB15699 | 507 | 652 | [
"DDInter1638",
"DDInter232"
] | Samarium (153Sm) lexidronam | Brexucabtagene autoleucel | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients rem... | Major | 2 | [
[
[
507,
25,
652
]
],
[
[
507,
24,
270
],
[
270,
24,
652
]
],
[
[
507,
64,
4
],
[
4,
24,
652
]
],
[
[
507,
25,
738
],
[
738,
24,
... | [
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Samarium (153Sm) lexidronam may lead to a major life threatening interaction w... |
DB00039 | DB15965 | 1,253 | 1,330 | [
"DDInter1380",
"DDInter1270"
] | Palifermin | Naxitamab | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
1253,
24,
1330
]
],
[
[
1253,
24,
1532
],
[
1532,
24,
1330
]
],
[
[
1253,
63,
268
],
[
268,
24,
1330
]
],
[
[
1253,
24,
1064
],
[
1064... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b ... |
DB01222 | DB13179 | 617 | 68 | [
"DDInter246",
"DDInter1882"
] | Budesonide | Troleandomycin | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | A macrolide antibiotic that is similar to erythromycin. | Major | 2 | [
[
[
617,
25,
68
]
],
[
[
617,
40,
251
],
[
251,
24,
68
]
],
[
[
617,
24,
1619
],
[
1619,
24,
68
]
],
[
[
617,
63,
723
],
[
723,
24,
... | [
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate int... | Budesonide (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction th... |
DB01244 | DB11827 | 762 | 433 | [
"DDInter192",
"DDInter669"
] | Bepridil | Ertugliflozin | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
762,
24,
433
]
],
[
[
762,
64,
521
],
[
521,
24,
433
]
],
[
[
762,
63,
885
],
[
885,
24,
433
]
],
[
[
762,
1,
939
],
[
939,
24,
... | [
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
... | Bepridil may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause... |
DB00106 | DB00289 | 618 | 847 | [
"DDInter4",
"DDInter132"
] | Abarelix | Atomoxetine | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Moderate | 1 | [
[
[
618,
24,
847
]
],
[
[
618,
24,
371
],
[
371,
40,
847
]
],
[
[
618,
25,
576
],
[
576,
1,
847
]
],
[
[
618,
23,
112
],
[
112,
62,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
],
[
... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone (Compound) resembles Atomoxetine (Compound)
Abarelix may lead to a major life threatening interaction when taken with Methadone and Methadone (Compound) resembles Atomoxetine (Compound)
Abarelix may caus... |
DB01197 | DB09146 | 1,603 | 489 | [
"DDInter292",
"DDInter978"
] | Captopril | Iron sucrose | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, ir... | Moderate | 1 | [
[
[
1603,
24,
489
]
],
[
[
1603,
40,
610
],
[
610,
24,
489
]
],
[
[
1603,
6,
12523
],
[
12523,
45,
386
],
[
386,
24,
489
]
],
[
[
1603,
... | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Captopril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may cause a moderate ... | Captopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Captopril (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Cholecalciferol (Compound) and Cholecalciferol may cause a moderate interaction that could... |
DB11718 | DB15035 | 927 | 503 | [
"DDInter640",
"DDInter1959"
] | Encorafenib | Zanubrutinib | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
927,
25,
503
]
],
[
[
927,
63,
1094
],
[
1094,
24,
503
]
],
[
[
927,
25,
982
],
[
982,
24,
503
]
],
[
[
927,
64,
868
],
[
868,
2... | [
[
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"Metre... | Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Encorafenib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may ... |
DB01030 | DB08881 | 869 | 868 | [
"DDInter1835",
"DDInter1925"
] | Topotecan | Vemurafenib | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
869,
24,
868
]
],
[
[
869,
6,
8374
],
[
8374,
45,
868
]
],
[
[
869,
18,
2546
],
[
2546,
45,
868
]
],
[
[
869,
7,
17764
],
[
17764,
... | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Topotecan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Topotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Topotecan (Compound) downregulates RAF1 (Gene) and RAF1 (Gene) is bound by Vemurafenib (Compound)
Topotecan (Compound) upregulates DHRS12 (Gene) and DHRS12 (Gene) is upregulated by Vemurafenib (Compound)
Topotecan (Compound) d... |
DB11979 | DB14723 | 1,320 | 159 | [
"DDInter625",
"DDInter1026"
] | Elagolix | Larotrectinib | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1320,
24,
159
]
],
[
[
1320,
24,
907
],
[
907,
23,
159
]
],
[
[
1320,
63,
479
],
[
479,
23,
159
]
],
[
[
1320,
62,
271
],
[
271,
... | [
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
[
... | Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil ... |
DB00448 | DB00530 | 1,215 | 1,195 | [
"DDInter1022",
"DDInter667"
] | Lansoprazole | Erlotinib | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Major | 2 | [
[
[
1215,
25,
1195
]
],
[
[
1215,
23,
1069
],
[
1069,
1,
1195
]
],
[
[
1215,
63,
883
],
[
883,
40,
1195
]
],
[
[
1215,
6,
7950
],
[
7950,
... | [
[
[
"Lansoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erlotinib"
]
],
[
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vandetanib"
],
[
"Vandetani... | Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Vandetanib and Vandetanib (Compound) resembles Erlotinib (Compound)
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Erlotinib (Compound)
La... |
DB01050 | DB08890 | 848 | 16 | [
"DDInter900",
"DDInter1069"
] | Ibuprofen | Linaclotide | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin deri... | Minor | 0 | [
[
[
848,
23,
16
]
],
[
[
848,
63,
1314
],
[
1314,
40,
16
]
],
[
[
848,
63,
59
],
[
59,
23,
16
]
],
[
[
848,
64,
886
],
[
886,
23,
... | [
[
[
"Ibuprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin (Compound) resembles Linaclotide (Compound)
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Etodolac and Etodolac may cause a minor interaction that can limit... |
DB00059 | DB01041 | 1,560 | 770 | [
"DDInter1404",
"DDInter1789"
] | Pegaspargase | Thalidomide | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
1560,
25,
770
]
],
[
[
1560,
24,
1668
],
[
1668,
1,
770
]
],
[
[
1560,
24,
609
],
[
609,
63,
770
]
],
[
[
1560,
24,
876
],
[
876,
... | [
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
],
[
"Len... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate inter... |
DB00238 | DB11921 | 188 | 1,019 | [
"DDInter1285",
"DDInter492"
] | Nevirapine | Deflazacort | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
188,
25,
1019
]
],
[
[
188,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
188,
24,
761
],
[
761,
24,
1019
]
],
[
[
188,
63,
1324
],
[
1324,
... | [
[
[
"Nevirapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib"... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagl... |
DB00086 | DB00554 | 1,167 | 1,027 | [
"DDInter1712",
"DDInter1478"
] | Streptokinase | Piroxicam | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Moderate | 1 | [
[
[
1167,
24,
1027
]
],
[
[
1167,
24,
1171
],
[
1171,
1,
1027
]
],
[
[
1167,
24,
222
],
[
222,
63,
1027
]
],
[
[
1167,
64,
1578
],
[
1578,... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam (Compound) resembles Piroxicam (Compound)
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that ... |
DB00624 | DB00959 | 1,561 | 1,486 | [
"DDInter1775",
"DDInter1191"
] | Testosterone | Methylprednisolone | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
1561,
24,
1486
]
],
[
[
1561,
1,
11347
],
[
11347,
40,
1486
]
],
[
[
1561,
40,
1581
],
[
1581,
1,
1486
]
],
[
[
1561,
63,
175
],
[
175... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortamate"
],
[
"Hydrocortamate",
"{u}... | Testosterone (Compound) resembles Hydrocortamate (Compound) and Hydrocortamate (Compound) resembles Methylprednisolone (Compound)
Testosterone (Compound) resembles Testolactone (Compound) and Testolactone (Compound) resembles Methylprednisolone (Compound)
Testosterone may cause a moderate interaction that could exacerb... |
DB00604 | DB09073 | 1,425 | 951 | [
"DDInter385",
"DDInter1379"
] | Cisapride | Palbociclib | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
1425,
24,
951
]
],
[
[
1425,
25,
318
],
[
318,
23,
951
]
],
[
[
1425,
64,
1230
],
[
1230,
23,
951
]
],
[
[
1425,
24,
479
],
[
479,
... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalop... | Cisapride may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Cisapride may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a minor intera... |
DB00295 | DB00543 | 475 | 87 | [
"DDInter1244",
"DDInter82"
] | Morphine | Amoxapine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
475,
24,
87
]
],
[
[
475,
25,
1119
],
[
1119,
1,
87
]
],
[
[
475,
64,
905
],
[
905,
40,
87
]
],
[
[
475,
64,
1174
],
[
1174,
1,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlordiazepoxide"
],
[
"Chlordiaz... | Morphine may lead to a major life threatening interaction when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Amoxapine (Compound)
Morphine may lead to a major life threatening interaction when taken with Lorazepam and Lorazepam (Compound) resembles Amoxapine (Compound)
Morphine may lead to a maj... |
DB04845 | DB08871 | 309 | 36 | [
"DDInter1001",
"DDInter666"
] | Ixabepilone | Eribulin | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
309,
24,
36
]
],
[
[
309,
5,
11579
],
[
11579,
44,
36
]
],
[
[
309,
6,
8785
],
[
8785,
45,
36
]
],
[
[
309,
54,
19142
],
[
19142,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Ixabepilone",
"{u} (Compound) treats {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is trea... | Ixabepilone (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Eribulin (Compound)
Ixabepilone (Compound) binds TUBB (Gene) and TUBB (Gene) is bound by Eribulin (Compound)
Ixabepilone (Compound) is included by Microtubule Inhibition (Pharmacologic Class) and Microtubule Inhibition (Phar... |
DB00795 | DB00855 | 50 | 213 | [
"DDInter1725",
"DDInter72"
] | Sulfasalazine | Aminolevulinic acid | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
50,
25,
213
]
],
[
[
50,
24,
785
],
[
785,
64,
213
]
],
[
[
50,
63,
245
],
[
245,
25,
213
]
],
[
[
50,
40,
161
],
[
161,
25,
... | [
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
],
[
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib and Capmatinib may lead to a major life threatening interaction when taken with Aminolevulinic acid
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glime... |
DB11560 | DB11901 | 1,678 | 913 | [
"DDInter1038",
"DDInter107"
] | Lesinurad | Apalutamide | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter assoc... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1678,
24,
913
]
],
[
[
1678,
63,
112
],
[
112,
23,
913
]
],
[
[
1678,
63,
600
],
[
600,
24,
913
]
],
[
[
1678,
24,
1320
],
[
1320,
... | [
[
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fl... |
DB00782 | DB01400 | 1,123 | 1,372 | [
"DDInter1535",
"DDInter1279"
] | Propantheline | Neostigmine | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. | Moderate | 1 | [
[
[
1123,
24,
1372
]
],
[
[
1123,
63,
751
],
[
751,
40,
1372
]
],
[
[
1123,
24,
61
],
[
61,
24,
1372
]
],
[
[
1123,
21,
28705
],
[
28705,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine (Compound) resembles Neostigmine (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate inter... |
DB00455 | DB09098 | 1,601 | 98 | [
"DDInter1091",
"DDInter1700"
] | Loratadine | Somatrem | Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1601,
24,
98
]
],
[
[
1601,
24,
159
],
[
159,
63,
98
]
],
[
[
1601,
23,
609
],
[
609,
24,
98
]
],
[
[
1601,
24,
152
],
[
152,
24... | [
[
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Loratadine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Loratadine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and ... |
DB06207 | DB08912 | 910 | 1,040 | [
"DDInter1667",
"DDInter462"
] | Silodosin | Dabrafenib | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenocepto... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
910,
24,
1040
]
],
[
[
910,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
910,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
910,
63,
1101
],
[
1101,... | [
[
[
"Silodosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Silodosin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Silodosin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Silodosin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Silodosin may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and... |
DB01299 | DB09268 | 698 | 1,662 | [
"DDInter1722",
"DDInter1464"
] | Sulfadoxine | Picosulfuric acid | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
698,
24,
1662
]
],
[
[
698,
63,
912
],
[
912,
24,
1662
]
],
[
[
698,
1,
1247
],
[
1247,
24,
1662
]
],
[
[
698,
40,
161
],
[
161,
... | [
[
[
"Sulfadoxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Sulfadoxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a... | Sulfadoxine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Sulfadoxine (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may ca... |
DB00215 | DB11703 | 1,230 | 405 | [
"DDInter388",
"DDInter9"
] | Citalopram | Acalabrutinib | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
1230,
24,
405
]
],
[
[
1230,
23,
951
],
[
951,
24,
405
]
],
[
[
1230,
25,
982
],
[
982,
63,
405
]
],
[
[
1230,
25,
918
],
[
918,
... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
],
[
... | Citalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Citalopram may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cau... |
DB00661 | DB06616 | 122 | 594 | [
"DDInter1928",
"DDInter224"
] | Verapamil | Bosutinib | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Major | 2 | [
[
[
122,
25,
594
]
],
[
[
122,
63,
883
],
[
883,
1,
594
]
],
[
[
122,
6,
8374
],
[
8374,
45,
594
]
],
[
[
122,
7,
5727
],
[
5727,
46... | [
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Verapamil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Verapamil (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregula... |
DB12457 | DB12500 | 1,180 | 283 | [
"DDInter1598",
"DDInter714"
] | Rimegepant | Fedratinib | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1180,
24,
283
]
],
[
[
1180,
24,
466
],
[
466,
62,
283
]
],
[
[
1180,
63,
351
],
[
351,
23,
283
]
],
[
[
1180,
63,
1419
],
[
1419,
... | [
[
[
"Rimegepant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Rimegepant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Rimegepant may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Rimegepant may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribo... |
DB00215 | DB00738 | 1,230 | 485 | [
"DDInter388",
"DDInter1420"
] | Citalopram | Pentamidine | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Major | 2 | [
[
[
1230,
25,
485
]
],
[
[
1230,
6,
12523
],
[
12523,
45,
485
]
],
[
[
1230,
21,
29097
],
[
29097,
60,
485
]
],
[
[
1230,
23,
112
],
[
112... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
]
],
[
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Pentam... | Citalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pentamidine (Compound)
Citalopram (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Pentamidine (Compound)
Citalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Met... |
DB00959 | DB01208 | 1,486 | 945 | [
"DDInter1191",
"DDInter1705"
] | Methylprednisolone | Sparfloxacin | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
1486,
25,
945
]
],
[
[
1486,
25,
739
],
[
739,
1,
945
]
],
[
[
1486,
64,
1176
],
[
1176,
1,
945
]
],
[
[
1486,
6,
4973
],
[
4973,
... | [
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomef... | Methylprednisolone may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Methylprednisolone may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Me... |
DB00582 | DB08816 | 1,622 | 578 | [
"DDInter1946",
"DDInter1802"
] | Voriconazole | Ticagrelor | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Major | 2 | [
[
[
1622,
25,
578
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
578
]
],
[
[
1622,
54,
19146
],
[
19146,
15,
578
]
],
[
[
1622,
21,
28646
],
[
286... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tic... | Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Voriconazole (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Ticagrelor (Compound)
Voriconazole (Compound) causes Unspecified d... |
DB00099 | DB01033 | 440 | 328 | [
"DDInter735",
"DDInter1156"
] | Filgrastim | Mercaptopurine | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Moderate | 1 | [
[
[
440,
24,
328
]
],
[
[
440,
24,
663
],
[
663,
23,
328
]
],
[
[
440,
24,
384
],
[
384,
63,
328
]
],
[
[
440,
24,
134
],
[
134,
24,... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and ... |
DB00041 | DB00899 | 1,648 | 411 | [
"DDInter38",
"DDInter1579"
] | Aldesleukin | Remifentanil | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depress... | Moderate | 1 | [
[
[
1648,
24,
411
]
],
[
[
1648,
24,
1322
],
[
1322,
40,
411
]
],
[
[
1648,
24,
704
],
[
704,
1,
411
]
],
[
[
1648,
24,
537
],
[
537,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil (Compound) resembles Remifentanil (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Remifentanil (Compound... |
DB00457 | DB09112 | 1,205 | 1,455 | [
"DDInter1511",
"DDInter1306"
] | Prazosin | Nitrous acid | Prazosin is a drug used to treat hypertension. Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists. Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTS... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
1205,
24,
1455
]
],
[
[
1205,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1205,
40,
1433
],
[
1433,
24,
1455
]
],
[
[
1205,
24,
433
],
[
433... | [
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
... | Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Prazosin (Compound) resembles Doxazosin (Compound) and Doxazosin may cause a moderate interaction that cou... |
DB00366 | DB00832 | 1,594 | 499 | [
"DDInter600",
"DDInter1446"
] | Doxylamine | Phensuximide | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Phensuximide is a member of the succinimide class with anticonvulsant properties. It suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. | Moderate | 1 | [
[
[
1594,
24,
499
]
],
[
[
1594,
63,
902
],
[
902,
40,
499
]
],
[
[
1594,
24,
157
],
[
157,
40,
499
]
],
[
[
1594,
24,
849
],
[
849,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phensuximide"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Phensuximide (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin and Ethotoin (Compound) resembles Phensuximide (Compound)
Doxy... |
DB00694 | DB01073 | 51 | 1,488 | [
"DDInter485",
"DDInter745"
] | Daunorubicin | Fludarabine | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
51,
24,
1488
]
],
[
[
51,
63,
1585
],
[
1585,
1,
1488
]
],
[
[
51,
5,
11555
],
[
11555,
44,
1488
]
],
[
[
51,
21,
28701
],
[
28701,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
],
... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Adenosine and Adenosine (Compound) resembles Fludarabine (Compound)
Daunorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Fludarabine (Compound)
Daunorubicin (Compound) cause... |
DB01118 | DB05294 | 33 | 1,069 | [
"DDInter76",
"DDInter1917"
] | Amiodarone | Vandetanib | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
33,
25,
1069
]
],
[
[
33,
63,
1195
],
[
1195,
40,
1069
]
],
[
[
33,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
33,
21,
28719
],
[
28719,
... | [
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Amiodarone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Amiodarone (Compound) causes Pain (Side Effect) and Pain (Side Effec... |
DB00563 | DB00598 | 663 | 1,523 | [
"DDInter1174",
"DDInter1013"
] | Methotrexate | Labetalol | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Moderate | 1 | [
[
[
663,
24,
1523
]
],
[
[
663,
25,
935
],
[
935,
1,
1523
]
],
[
[
663,
24,
954
],
[
954,
1,
1523
]
],
[
[
663,
25,
1274
],
[
1274,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketoprofen"
],
[
"Ketopro... | Methotrexate may lead to a major life threatening interaction when taken with Ketoprofen and Ketoprofen (Compound) resembles Labetalol (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Labetalol (Compound)
Methotrexate ma... |
DB00211 | DB06694 | 1,290 | 31 | [
"DDInter1213",
"DDInter1952"
] | Midodrine | Xylometazoline (nasal) | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Xylometazoline is an alkylbenzene. | Moderate | 1 | [
[
[
1290,
24,
31
]
],
[
[
1290,
6,
5700
],
[
5700,
45,
31
]
],
[
[
1290,
24,
144
],
[
144,
63,
31
]
],
[
[
1290,
24,
688
],
[
688,
2... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Midodrine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1D"
],
[
"ADRA1D",
"{u} (Gene) is bound by {v} (Compound)... | Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Midodrine (Compound) binds ADRA1D (Gene) and ADRA1D (Gene) is bound by Xylometazoline (Compound)
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol ma... |
DB00108 | DB00704 | 1,066 | 267 | [
"DDInter1268",
"DDInter1263"
] | Natalizumab | Naltrexone | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
1066,
24,
267
]
],
[
[
1066,
25,
1583
],
[
1583,
63,
267
]
],
[
[
1066,
24,
1627
],
[
1627,
63,
267
]
],
[
[
1066,
25,
1101
],
[
1101,... | [
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Sarilumab... | Natalizumab may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may caus... |
DB01050 | DB08820 | 848 | 1,478 | [
"DDInter900",
"DDInter997"
] | Ibuprofen | Ivacaftor | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
848,
24,
1478
]
],
[
[
848,
6,
4973
],
[
4973,
45,
1478
]
],
[
[
848,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
848,
24,
318
],
[
318,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Ibuprofen",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Ibuprofen (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ivacaftor (Compound)
Ibuprofen (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopra... |
DB00382 | DB00986 | 62 | 1,192 | [
"DDInter1734",
"DDInter834"
] | Tacrine | Glycopyrronium | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Moderate | 1 | [
[
[
62,
24,
1192
]
],
[
[
62,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
62,
24,
262
],
[
262,
24,
1192
]
],
[
[
62,
63,
701
],
[
701,
24... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidini... |
DB00005 | DB00163 | 1,057 | 1,461 | [
"DDInter687",
"DDInter1943"
] | Etanercept | Vitamin E | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Minor | 0 | [
[
[
1057,
23,
1461
]
],
[
[
1057,
25,
76
],
[
76,
62,
1461
]
],
[
[
1057,
25,
581
],
[
581,
23,
1461
]
],
[
[
1057,
24,
66
],
[
66,
... | [
[
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
],
[
"Mogamulizu... | Etanercept may lead to a major life threatening interaction when taken with Mogamulizumab and Mogamulizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Etanercept may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a minor inte... |
DB00987 | DB10583 | 1,224 | 949 | [
"DDInter460",
"DDInter415"
] | Cytarabine | Clostridium tetani toxoid antigen (formaldehyde inactivated) | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
1224,
24,
949
]
],
[
[
1224,
63,
589
],
[
589,
24,
949
]
],
[
[
1224,
25,
1377
],
[
1377,
24,
949
]
],
[
[
1224,
35,
1488
],
[
1488,
... | [
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when t... | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Cytarabine may lead to a major life threatening interaction when... |
DB00445 | DB01242 | 322 | 1,237 | [
"DDInter655",
"DDInter410"
] | Epirubicin | Clomipramine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
322,
24,
1237
]
],
[
[
322,
25,
684
],
[
684,
1,
1237
]
],
[
[
322,
24,
1164
],
[
1164,
1,
1237
]
],
[
[
322,
63,
508
],
[
508,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thiori... | Epirubicin may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Clomipramine (Compound)
Epi... |
DB00414 | DB00691 | 590 | 1,058 | [
"DDInter16",
"DDInter1237"
] | Acetohexamide | Moexipril | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Moderate | 1 | [
[
[
590,
24,
1058
]
],
[
[
590,
24,
1638
],
[
1638,
1,
1058
]
],
[
[
590,
24,
954
],
[
954,
40,
1058
]
],
[
[
590,
24,
115
],
[
115,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Moexipril"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Moexipril (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril (Compound) resembles Moexipril (Comp... |
DB04951 | DB15066 | 187 | 445 | [
"DDInter1477",
"DDInter821"
] | Pirfenidone | Givosiran | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Major | 2 | [
[
[
187,
25,
445
]
],
[
[
187,
24,
850
],
[
850,
24,
445
]
],
[
[
187,
63,
482
],
[
482,
24,
445
]
],
[
[
187,
64,
1377
],
[
1377,
2... | [
[
[
"Pirfenidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Ti... |
DB00649 | DB01229 | 231 | 973 | [
"DDInter1710",
"DDInter1377"
] | Stavudine | Paclitaxel | A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
231,
24,
973
]
],
[
[
231,
24,
310
],
[
310,
63,
973
]
],
[
[
231,
7,
9489
],
[
9489,
46,
973
]
],
[
[
231,
21,
28779
],
[
28779,
... | [
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Stavudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Stavudine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Stavudine (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Paclitaxel (Compound)
Stavudine ... |
DB06212 | DB09098 | 165 | 98 | [
"DDInter1833",
"DDInter1700"
] | Tolvaptan | Somatrem | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
165,
24,
98
]
],
[
[
165,
24,
159
],
[
159,
63,
98
]
],
[
[
165,
64,
609
],
[
609,
24,
98
]
],
[
[
165,
63,
79
],
[
79,
24,
... | [
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Tolvaptan may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin ... |
DB00480 | DB11732 | 1,668 | 1,097 | [
"DDInter1035",
"DDInter1027"
] | Lenalidomide | Lasmiditan | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1668,
24,
1097
]
],
[
[
1668,
24,
478
],
[
478,
24,
1097
]
],
[
[
1668,
64,
1064
],
[
1064,
24,
1097
]
],
[
[
1668,
25,
1510
],
[
1510... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[... | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Lenalidomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may caus... |
DB00108 | DB00531 | 1,066 | 450 | [
"DDInter1268",
"DDInter456"
] | Natalizumab | Cyclophosphamide | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Major | 2 | [
[
[
1066,
25,
450
]
],
[
[
1066,
25,
1001
],
[
1001,
40,
450
]
],
[
[
1066,
64,
491
],
[
491,
23,
450
]
],
[
[
1066,
25,
377
],
[
377,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclophosphamide"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mechlorethamine"
],
[
"Mechloretham... | Natalizumab may lead to a major life threatening interaction when taken with Mechlorethamine and Mechlorethamine (Compound) resembles Cyclophosphamide (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a minor interaction tha... |
DB00258 | DB01344 | 666 | 1,231 | [
"DDInter270",
"DDInter1830"
] | Calcium acetate | Tolevamer | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Moderate | 1 | [
[
[
666,
24,
1231
]
],
[
[
666,
24,
1152
],
[
1152,
24,
1231
]
],
[
[
666,
24,
1482
],
[
1482,
63,
1231
]
],
[
[
666,
24,
1152
],
[
1152,
... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Digitoxi... |
DB00564 | DB06168 | 1,236 | 1,531 | [
"DDInter293",
"DDInter281"
] | Carbamazepine | Canakinumab | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1236,
24,
1531
]
],
[
[
1236,
25,
1362
],
[
1362,
63,
1531
]
],
[
[
1236,
25,
1213
],
[
1213,
24,
1531
]
],
[
[
1236,
63,
1031
],
[
10... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olapa... | Carbamazepine may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Carbamazepine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate int... |
DB01246 | DB08868 | 820 | 1,011 | [
"DDInter45",
"DDInter737"
] | Alimemazine | Fingolimod | A phenothiazine derivative that is used as an antipruritic. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
820,
25,
1011
]
],
[
[
820,
6,
8374
],
[
8374,
45,
1011
]
],
[
[
820,
21,
28859
],
[
28859,
60,
1011
]
],
[
[
820,
62,
1247
],
[
1247,... | [
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Alimemazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fingo... | Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Alimemazine (Compound) causes Atrioventricular block (Side Effect) and Atrioventricular block (Side Effect) is caused by Fingolimod (Compound)
Alimemazine may cause a minor interaction that can limit clinical effects when tak... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.